06:51 AM EDT, 08/03/2026 (MT Newswires) -- Genflow Biosciences (GENF.L) said Monday the US Patent and Trademark Office granted Track One prioritized examination for its foundational in-licensed US SIRT6 centenarian-derived patent application. The patent office also published the company's US patent application covering the use of its SIRT6 centenarian-derived variant in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Genflow said neither the publication nor the Track One designation guarantees that a patent will be granted. A similar patent application in Europe is at the last stage before the European Patent Office, the company noted. The timing of grant remains subject to completion of the regulator's formal procedures.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.